
A bipartisan group of lawmakers has formed the Congressional Community Pharmacy Coalition to advocate on pharmacy issues.
A bipartisan group of lawmakers has formed the Congressional Community Pharmacy Coalition to advocate on pharmacy issues.
FDA proposes chlorofluorocarbon (CFC) removal from epinephrine inhalers.
Wyeth's new Advil Maximum Strength waiting for FDA approval.
Emergency contraception policy sparks debate.
California pharmacy board is stepping up its enforcement of its pharmacy consultation with stiffer fines.
In the face of increasing pharmacy costs at Delaware, Maryland, and Virginia pharmacies, health plans push beneficiaries to mail-order facilities
Rite Aid integration of Brooks Eckerd stores progressing
Baxa replaces malfunctioning IV mixing software
FDA approves 300-mg strength of clopidogrel
CMS announces details of the 2008 prescription drug plans
Teamsters at AmerisourceBergen to rally for fair contract settlement.
Albemarle to increase price of ibuprofen
NACDS applauds passage of House bill to delay tamper-resistant paper requirement
QIO sets up new MTM program for Maryland and District of Columbia
PhRMA testifies to Congress about the threat of drug counterfeiting
Wal-Mart expands its $4 generic plan to include more generics and adds birth control Rxs for $9.
Massachusetts hospitals paying for errors
FDA warns of adverse effects with buccal fentanyl use.
The Senate passed legislation delaying implementation of the Medicaid rule mandating tamper-resistant Rx pads and awaits House action.
Generic versions of Marinol should be classified as Schedule III when they are approved, according to the Drug Enforcement Administration
Medicare keeping limits on anemia drugs
Genetic differences predict anti-inflammatory benefits from nutritional products
Shop 'n Save Pharmacy to provide Vitality Check wellness service
NACDS Foundation Chain Pharmacy Industry Profile highlights role of pharmacists
College of Pharmacy gets new home
NACDS debunks New York Times article, "The 'Poisonous Cocktail' of Multiple Drugs"
Inflated average wholesale prices issued by two publishers have resulted in high costs for consumers, who have filed class-action suits against them.
Oripavine is designated a Schedule II controlled substance by the Drug Enforcement Administration
National Quality Forum releases standards for substance abuse treatment